May was another strong month for healthtech funding, with investors continuing to back AI, drug discovery, diagnostics, and chronic care startups.
The biggest round came from Isomorphic Labs, which raised $2.1 billion to accelerate AI-powered drug discovery. Elsewhere, companies like Nourish, Garner Health, Commure, Triomics, and ClearNote Health secured fresh capital to expand their platforms and bring new healthcare innovations to market.
Here’s a look at the healthtech funding rounds announced in May 2026.
1. Isomorphic Labs
Funds raised: US $2.1 billion
Series: Series B
Investors: Thrive Capital (lead), Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
About: Isomorphic Labs is an AI-first drug discovery company spun out of Google DeepMind. It uses advanced AI models, including technology derived from AlphaFold, to accelerate the design and development of new medicines across multiple disease areas.
How it plans to use the funds: Develop its AI drug design engine (IsoDDE), expand its therapeutic pipeline toward clinical trials, scale global operations, and hire AI, engineering, drug discovery, and clinical talent.
2. Nourish
Funds raised: US$ 100 million
Series: Series C
Investors: Menlo Ventures (lead), Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak, and Operator Partners.
About: Nourish is a virtual metabolic health clinic that combines registered dietitians, AI-powered care, lab testing, and GLP-1 medication management to help patients manage obesity, diabetes, and other chronic conditions.
How it plans to use the funds: Expand its clinical network, invest in AI tools for patients and providers, grow its physician-led metabolic care model, and deepen partnerships with health plans, employers, and health systems.
3. Garner Health
Funds raised: US$ 100 million
Series: Series E
Investors: Index Ventures (lead), Kleiner Perkins, Redpoint, Thrive Capital, Sequoia Capital, Founders Fund, and Kaiser Permanente Ventures.
About: Garner Health is a healthcare navigation platform that helps employers and health plans guide members to high-quality providers using claims data, AI, and proprietary physician quality metrics.
How it plans to use the funds: Expand its provider intelligence platform, accelerate the rollout of AI-powered products, and extend its benefits coverage to millions of additional members.
4. Commure
Funds raised: US$ 70 million
Series: Growth financing / Strategic funding round
Investors: General Catalyst (lead), Sequoia Capital, Morgan Stanley, and Kirkland & Ellis.
About: Commure is a healthcare AI platform that helps health systems and medical practices automate administrative and clinical workflows. Its AI agents are used for revenue cycle management, clinical documentation, coding, billing, and other operational tasks.
How it plans to use the funds: Scale its revenue cycle and practice management platform, advance its AI agent infrastructure, and expand into global healthcare markets.
5. ClearNote Health
Funds raised: US$ 52 million
Series: Series D
Investors: Mattias Westman (lead), Sandy Weill, Dr. Stephen Quake, and other institutional investors.
About: ClearNote Health is a cancer diagnostics company developing blood-based tests for the early detection of hard-to-diagnose cancers. Its AI-powered epigenomics platform analyzes biological signals in blood samples to identify cancer at earlier stages.
How it plans to use the funds: Expand commercialization of its cancer detection tests, support clinical studies, scale operations, advance product development, and broaden global access to its diagnostic portfolio.
6. 9amHealth
Funds raised: US$ 26 million
Series: Series B
Investors: Define Ventures (lead), SemperVirens VC, Catalio Capital Management, and NewHealth Ventures.
About: 9amHealth is a virtual specialty care platform focused on cardiometabolic conditions such as obesity, diabetes, hypertension, and high cholesterol.
How it plans to use the funds: Expand beyond cardiometabolic care into additional high-cost chronic conditions while scaling its clinical operations and AI-powered care delivery platform.
7. Triomics
Funds raised: US$ 22 million
Series: Series B
Investors: Battery Ventures (lead), Nexus Venture Partners, Lightspeed, Y Combinator, Oncology Ventures, and Precision Health Informatics.
About: Triomics develops oncology-specific AI software that helps cancer centers automate workflows such as clinical trial matching, patient chart summarization, and cancer registry reporting.
How it plans to use the funds: Expand adoption across cancer centers, grow its AI and engineering teams, and strengthen life sciences partnerships.
8. Lucis
Funds raised: US$ 20 million
Series: Series A
Investors: Singular (lead), General Catalyst, Y Combinator, and several angel investors.
About: Lucis is a preventive health platform that uses blood biomarker analysis and an AI-powered health companion to deliver personalized health recommendations.
How it plans to use the funds: Expand across Europe, enhance its AI-driven platform, and continue investing in personalized preventive care.
9. Signos
Funds raised: US$ 20 million
Series: Not disclosed
Investors: Dexcom, GV (Google Ventures), and Blue Cross Blue Shield of Alabama.
About: Signos is a metabolic health company that combines continuous glucose monitoring, AI-driven insights, and personalized coaching to help users manage weight and improve metabolic health.
How it plans to use the funds: Expand access to its platform, deepen its partnership with Dexcom, and accelerate adoption of CGM-based metabolic health tools.
10. Dandelion Health
Funds raised: US$ 14 million
Series: Series A
Investors: Healthier Capital (lead), Colle Capital, Primary Venture Partners, Moxxie Ventures, and Convergent Ventures.
About: Dandelion Health is a clinical intelligence platform that helps life sciences and pharmaceutical companies use multimodal clinical data and AI to improve drug development, clinical trials, and precision medicine.
How it plans to use the funds: Expand pharmaceutical partnerships, strengthen its data infrastructure, and grow its commercial and scientific teams.
11. MindMaze Therapeutics
Funds raised: ~US$ 9.7 million (CHF 8 million)
Series: Strategic equity financing
Investors: Neuro.io Group SA
About: MindMaze Therapeutics is a neurotechnology company developing AI-powered therapies for neurological disorders. Its platform combines neuroscience, digital therapeutics, and data-driven treatment approaches to improve patient outcomes.
How it plans to use the funds: Expand its presence in the U.S. market, accelerate commercialization efforts, and advance development of its neurotherapeutic solutions.
Wrapping up
May’s funding activity highlights several themes shaping healthcare innovation in 2026.
AI continues to dominate investor interest, not only in drug discovery but also in clinical operations, diagnostics, and care delivery.
At the same time, startups focused on chronic disease management, preventive health, and personalized medicine continue to attract significant capital as healthcare systems seek more scalable and proactive models of care.
With more than $2.5 billion raised across the companies featured in this roundup, investors are placing substantial bets on technologies that can improve efficiency, accelerate research, and deliver better patient outcomes.
As the year progresses, it will be worth watching how these companies translate fresh capital into clinical, commercial, and regulatory milestones.
—
Source: HealthTech Alpha’s funding data
We’re the exclusive HealthTech Alpha partners in India! Reach out if you’re looking for deeper market intelligence or strategic perspectives.
